Table of Contents Author Guidelines Submit a Manuscript
Tuberculosis Research and Treatment
Volume 2013, Article ID 129723, 6 pages
http://dx.doi.org/10.1155/2013/129723
Clinical Study

Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA

1Division of Infectious Diseases and International Health, University of Virginia, P.O. Box 801340, Charlottesville, VA 22908-1340, USA
2Tuberculosis Control and Prevention, Virginia Department of Health, Richmond, VA, USA

Received 18 July 2013; Accepted 3 October 2013

Academic Editor: T. Ottenhoff

Copyright © 2013 Scott K. Heysell et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. E. Dooley and R. E. Chaisson, “Tuberculosis and diabetes mellitus: convergence of two epidemics,” The Lancet Infectious Diseases, vol. 9, no. 12, pp. 737–746, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. C. R. Stevenson, N. G. Forouhi, G. Roglic et al., “Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence,” BMC Public Health, vol. 7, article 234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. C. Y. Jeon and M. B. Murray, “Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies,” PloS Medicine, vol. 5, no. 7, article e152, 2008. View at Publisher · View at Google Scholar
  4. B. Alisjahbana, E. Sahiratmadja, E. J. Nelwan et al., “The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis,” Clinical Infectious Diseases, vol. 45, no. 4, pp. 428–435, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. K. E. Dooley, T. Tang, J. E. Golub, S. E. Dorman, and W. Cronin, “Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis,” The American Journal of Tropical Medicine and Hygiene, vol. 80, no. 4, pp. 634–639, 2009. View at Google Scholar · View at Scopus
  6. M. A. Baker, A. D. Harries, C. Y. Jeon et al., “The impact of diabetes on tuberculosis treatment outcomes: a systematic review,” BMC Medicine, vol. 9, article 81, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. S. K. Heysell, J. L. Moore, S. J. Keller, and E. R. Houpt, “Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA,” Emerging Infectious Diseases, vol. 16, no. 10, pp. 1546–1553, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. S. K. Heysell, C. Mtabho, S. Mpagama et al., “Plasma drug activity assay for treatment optimization in tuberculosis patients,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 12, pp. 5819–5825, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. C. A. Peloquin, “Therapeutic drug monitoring in the treatment of tuberculosis,” Drugs, vol. 62, no. 15, pp. 2169–2183, 2002. View at Google Scholar · View at Scopus
  10. S. K. Heysell, J. L. Moore, D. Dodge, D. Staley, and E. Houpt, “Guidelines for the use of therapeutic drug level monitoring in Virginia: the first year,” in Proceedings of the Annual Meeting of the National Tuberculosis Controller’s Association, Atlanta, Ga, USA, 2012.
  11. Virginia Department of Health, “Recommendations and procedures for the use of therapeutic drug monitoring in clients with drug-susceptible tuberculosis receiving directly-observed therapy,” http://www.vdh.virginia.gov/epidemiology/DiseasePrevention/Programs/Tuberculosis/documents/TDMRecommendationsandProceduresRrevised082013Final.pdf.
  12. Virginia Department of Health, Office of Epidemiology, and Division of Disease Prevention, 2011 Annual Tuberculosis Surveillance Report, 2012.
  13. H. M. J. Nijland, R. Ruslami, J. E. Stalenhoef et al., “Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes,” Clinical Infectious Diseases, vol. 43, no. 7, pp. 848–854, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Ruslami, H. M. J. Nijland, I. G. N. Adhiarta et al., “Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 3, pp. 1068–1074, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Requena-Méndez, G. Davies, A. Ardrey et al., “Pharmacokinetics of rifampin in Peruvian tuberculosis patients with and without comorbid diabetes or HIV,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 5, pp. 2357–2363, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. P. R. Gwilt, R. R. Nahhas, and W. G. Tracewell, “The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans,” Clinical Pharmacokinetics, vol. 20, no. 6, pp. 477–490, 1991. View at Google Scholar · View at Scopus
  17. Y. Ashokraj, K. J. Kaur, I. Singh et al., “In vivo dissolution: predominant factor affecting the bioavailability of rifampicin in its solid oral dosage forms,” Clinical Research and Regulatory Affairs, vol. 25, no. 1, pp. 1–12, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. M. J. Boeree, A. H. Diacon, R. Dawson, A. Venter et al., “What is the “right” dose of rifampin?, abstract #148LB,” in Proceedings of the Conference on Retroviruses and Opportunistic Infections, Atlanta, Ga, USA, 2013.
  19. A. H. Diacon, R. F. Patientia, A. Venter et al., “Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 8, pp. 2994–2996, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. J. van Ingen, R. E. Aarnoutse, P. R. Donald et al., “Why do we use 600 mg of rifampicin in tuberculosis treatment?” Clinical Infectious Diseases, vol. 52, no. 9, pp. e194–e199, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Maâlej, N. Belhaoui, M. Bourguiba et al., “Pulmonary tuberculosis and diabetes: retrospective study of 60 patients in Tunisia,” La Presse Médicale, vol. 38, no. 1, pp. 20–24, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. B. I. Restrepo, S. P. Fisher-Hoch, B. Smith, S. Jeon, M. H. Rahbar, and J. B. McCormick, “Mycobacterial clearance from sputum is delayed during the first phase of treatment in patients with diabetes,” The American Journal of Tropical Medicine and Hygiene, vol. 79, no. 4, pp. 541–544, 2008. View at Google Scholar · View at Scopus
  23. C. Y. Jeon, A. D. Harries, M. A. Baker et al., “Bi-directional screening for tuberculosis and diabetes: a systematic review,” Tropical Medicine and International Health, vol. 15, no. 11, pp. 1300–1314, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Balakrishnan, S. Vijayan, S. Nair, J. Subramoniapillai et al., “High diabetes prevalence among tuberculosis cases in Kerala, India,” PLoS ONE, vol. 7, no. 10, Article ID e46502, 2012. View at Google Scholar